EPISTOP, NCT04976036: Efficacy of Nintedanib for Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Patients |
|
|
| Recruiting | 2 | 48 | Europe | Nintedanib, Placebo | Dr. Romain Lazor, Boehringer Ingelheim | Telangiectasia, Hereditary Hemorrhagic | 04/24 | 09/24 | | |
| Recruiting | N/A | 500000 | Europe | | University of Bern, Federal Office of Public Health, Switzerland, Universitäts-Kinderspital Zürich, University Children's Hospital Basel, Insel Gruppe AG, University Hospital Bern, University Hospital, Zürich, Centre Hospitalier Universitaire Vaudois, University Hospital, Geneva, Proraris Allianz seltener Krankheiten, Kosek National Coordination Rare Diseases Switzerland, Orphanet Suisse, University of Zurich, Kantonsspital Aarau, Ente Ospedaliero Cantonale, Bellinzona, Cantonal Hospital of St. Gallen, Ostschweizer Kinderspital, University Hospital, Basel, Switzerland, Balgrist University Hospital, Centro Malattie Rare della Svizzera Italiana | Rare Diseases | 01/71 | 01/71 | | |
